Biopharma Stocks Targeting Crohn’s Disease In $13.7 Billion Market (STAB, ARNA, GILD and RDHL)

3D render of a medical background with DNA strands

Biopharmaceutical stocks are targeting Crohn’s Disease in developing drugs in 2022. Research finds that this is a $13.7 billion market ripe for sector stock catalysts such as profit and dividends. 


Here are catalysts for buying into biopharmaceutical stocks targeting the development of Crohn’s Disease drugs in 2022:

— The market for Crohn’s Disease drug treatment is $13.7 billion, research reports. The sector is growing an annual CAGR of greater than 7.6%.

— M&A activity has heightened among Crohn’s Disease biopharmaceutical stocks. This indicates profitability as larger drug companies acquire smaller ones operating clinical studies for Crohn candidate drugs in clinical tests possibly leading to commercialization. 

— Crohn’s Disease is an active marketplace, leading to becoming a global volume and profit marker. In the U.S. alone, there are greater than 825,000 cases.

— Clinical studies for inflammatory diseases like Crohn’s Disease are a smart sector investment. Stock purchases in biopharmaceuticals in this sector can pay off big as drug candidates are in R&D development.

— Ongoing research trials for inflammatory diseases are focused on developing commercialized drugs in the marketplace.

STAB Receives Board Approval To Begin Clinical Trial For Crohn’s

Place STAB stock on your watch list as it is now progressing with next-gen R&D on its proprietary platform. Its leading drug candidate may become standard care for the treatment of Crohn’s.

Statera Biopharma, Inc. (NASDAQ: STAB) is advancing next-gen research activities based on proprietary compositions from its own STAT-200 platform. The result is that promising new compositions are being developed to treat a range of inflammatory diseases. These include clinical programs for Crohn’s disease.

The Company has received Central Institutional Board Review (IRB) to conduct a Phase 3 Clinical Trial for its STAT-201 in the treatment of pediatric Crohn’s disease. This is an inflammatory condition of the gastrointestinal tract.

Michael K. Handley, President, and CEO of the biopharmaceutical company,  says STAT-201 is STAB’s most advanced drug candidate and is at trial to prove it can restore intestinal barrier function. It would then become a standard of care in the treatment of Crohn’s.


—Arena (NASDAQ: ARNA) has agreed to be acquired by Pfizer (NYSE: PFE) as M&A intensifies in the Biopharmaceutical world. Its leading drug candidate is Etrasimod, which is now being tested for the treatment of Crohn’s Disease. 

It is an oral drug that partially and reverses lymphocyte levels at inflammation sites. It also maintains immune function. Pfizer sees it dovetailing with its own large anti-inflammatory drug portfolio. 

— Redhill Biopharma (NASDAQ: RDHL) is scheduled to post quarterly earnings tomorrow before the market opens for trading. The 50-day moving average for this stock is $2.32.

This is a company focused on developing gastrointestinal drugs and treating infectious diseases. Its leading drug candidate is Movantik. It is designed to treat opioid induced constipation in adults and chronic non-cancer pain. RDHL is a specialty company that focuses on inflammatory diseases of the intestines, including Crohn’s.


— Gilead Sciences (NASDAQ: GILD) is an American biopharmaceutical company with several investigational trials of compounds that can be important in the treatment of life-threatening diseases.

It is currently conducting a Phase 3 study against Crohn’s Disease with its JAK-1 inhibitor. It is conducting Phase 1 trials of its TPL2 and IRAK4 in the treatment of inflammatory bowel disease. It is also overseeing trials of candidate drugs in the treatment of Lupus and Rheumatoid Arthritis.    Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at

This article is part of a sponsored investor education program.